Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 5,397 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Random Match Clear all
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

NCT04766476
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
BMS-963272, Placebo matching BMS-963272
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
19
States / cities
Cullman, Alabama • Chandler, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial

NCT00835289
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
n-3 polyunsaturated fatty acids, Placebo
Dietary Supplement · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1

NCT02770716
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Terlipressin, Placebo
Drug · Other
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 29, 2026, 6:49 AM EDT
Terminated Phase 4 Interventional Results available

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

NCT04558125
View directory record Official record
Conditions
Pulmonary Embolism, COVID
Interventions
TNKase, Placebo, Enoxaparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

NCT04874350
View directory record Official record
Conditions
Liver Cirrhosis, Sarcopenia
Interventions
LPCN 1148, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00286494
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and pioglitazone, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Not applicable Interventional

Behavioral Therapy for Tourette Syndrome

NCT03019731
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Therapist-directed Behavioral Therapy, Home-based DVD Therapy
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
7 Years to 13 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 29, 2026, 6:49 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Atacicept in Subjects With IgA Nephropathy

NCT04716231
View directory record Official record
Conditions
IgA Nephropathy, Berger Disease
Interventions
Atacicept, Placebo to match Atacicept
Biological · Other
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 29, 2026, 6:49 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

NCT07225972
View directory record Official record
Conditions
CMV, AdV Infection, AdV Reactivation, Adenovirus, Cytomegalovirus Infections
Interventions
Standard of Care Antiviral medications, Viral CTLs
Drug · Biological
Lead sponsor
New York Medical College
Other
Eligibility
1 Day to 30 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Valhalla, New York • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

NCT01942265
View directory record Official record
Conditions
Influenza
Interventions
AS03, MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
5
States / cities
Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 29, 2026, 6:49 AM EDT
Recruiting Phase 3 Interventional

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets

NCT07868419
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
NAL ER, Placebo
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Wilmington, Delaware • North Miami Beach, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

NCT03224351
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 29, 2026, 6:49 AM EDT
Recruiting Phase 3 Interventional

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

NCT07201129
View directory record Official record
Conditions
Nephritis, Lupus, Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
14
States / cities
Doral, Florida • Kissimmee, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of a Hydrolyzed Chicken Collagen Type II in Alleviating Joint Discomfort

NCT04955353
View directory record Official record
Conditions
Joint Discomfort
Interventions
AVC-H2, Placebo
Dietary Supplement
Lead sponsor
Avicenna Nutraceutical
Other
Eligibility
40 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

NCT04846881
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants

NCT02389881
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-058, TAK-058 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austsitn, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 29, 2026, 6:49 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Atacicept in IgA Nephropathy

NCT02808429
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Placebo, Atacicept 25 mg, Atacicept 75 mg
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Glendale, Arizona • Chula Vista, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

NCT04208412
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900, Placebo
Drug · Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Scottsdale, Arizona • Centennial, Colorado • Chevy Chase, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT04630028
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Ustekinumab Dose Based on BSA and Body Weight, Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

NCT04023994
View directory record Official record
Conditions
Alzheimers Disease
Interventions
RO7126209, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 29, 2026, 6:49 AM EDT
Recruiting Phase 2 Interventional

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

NCT07553637
View directory record Official record
Conditions
Treatment-resistant Depression (TRD)
Interventions
ALTO-207, Placebo
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
53
States / cities
Dothan, Alabama • Phoenix, Arizona • Chino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

NCT01148537
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 29, 2026, 6:49 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437
View directory record Official record
Conditions
Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ponsegromab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 29, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

NCT04709575
View directory record Official record
Conditions
Allergic Rhinitis, Conjunctivitis
Interventions
REGN5713, REGN5714, REGN5715, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
14
States / cities
Bangor, Maine • Baltimore, Maryland • Plymouth, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 29, 2026, 6:49 AM EDT